• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD133 作为卵巢癌发生的重要标志物。

CD133 Act as an Essential Marker in Ovarian Carcinogenesis.

机构信息

Department of Anatomical Pathology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.

Department of Histology, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3525-3531. doi: 10.31557/APJCP.2021.22.11.3525.

DOI:10.31557/APJCP.2021.22.11.3525
PMID:34837909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9068199/
Abstract

OBJECTIVE

To analyze the role of cancer stem cells (CSC) in ovarian carcinogenesis through the identification of CD133 expression in the normal ovary (NO), serous cystadenoma (SC), borderline serous tumour (BST), low-grade serous carcinoma (LGSC), and high-grade serous carcinoma (HGSC).

MATERIALS AND METHODS

A total of 48 tissue samples contain 5 NO, 10 SC, 5 BST, 8 LGSC, and 20 HGSC were stained with anti-CD133 antibody by immunohistochemical protocol. The difference in the H-score of CD133 expression between groups and their relationship to age, histomorphology, and localization was analyzed.

RESULTS

CD133 expression varied among tumor groups, with clinicopathologic parameters showing diverse associations (age p = 0.773; histomorphology p = 0.001; and localization p = 0.026). The comparison of CD133 H-scores differed significantly between each group (p = 0.0031), in which precursor and malignant lesions possessed more robust CD133 expression.

CONCLUSION

The presence of CD133 cellular expression and localization in different types of serous ovarian tumours suggests that these markers are involved in ovarian tumorigenesis.

摘要

目的

通过鉴定卵巢正常组织(NO)、浆液性囊腺瘤(SC)、交界性浆液性肿瘤(BST)、低级别浆液性癌(LGSC)和高级别浆液性癌(HGSC)中 CD133 的表达,分析癌症干细胞(CSC)在卵巢发生中的作用。

材料与方法

共对 48 份组织样本进行了分析,其中包括 5 份 NO、10 份 SC、5 份 BST、8 份 LGSC 和 20 份 HGSC,通过免疫组织化学方案用抗 CD133 抗体对其进行染色。分析了各组间 CD133 表达的 H 评分差异及其与年龄、组织形态学和定位的关系。

结果

CD133 的表达在肿瘤组之间存在差异,临床病理参数的相关性也各不相同(年龄 p=0.773;组织形态学 p=0.001;定位 p=0.026)。各组间 CD133 H 评分的比较差异有统计学意义(p=0.0031),其中前体和恶性病变具有更强的 CD133 表达。

结论

不同类型浆液性卵巢肿瘤中 CD133 细胞表达和定位的存在提示这些标志物参与了卵巢肿瘤的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707f/9068199/3a0196ff5623/APJCP-22-3525-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707f/9068199/d95fb21ce54c/APJCP-22-3525-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707f/9068199/3a0196ff5623/APJCP-22-3525-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707f/9068199/d95fb21ce54c/APJCP-22-3525-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/707f/9068199/3a0196ff5623/APJCP-22-3525-g002.jpg

相似文献

1
CD133 Act as an Essential Marker in Ovarian Carcinogenesis.CD133 作为卵巢癌发生的重要标志物。
Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3525-3531. doi: 10.31557/APJCP.2021.22.11.3525.
2
Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.烟酰胺 N-甲基转移酶过表达可能与卵巢癌预后不良相关。
J Obstet Gynaecol. 2021 Feb;41(2):248-253. doi: 10.1080/01443615.2020.1732891. Epub 2020 Apr 14.
3
A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.一种以CD44和prominin-1(CD133)作为选择标记物来分离和鉴定癌症干细胞样细胞的合理方法。
Oncotarget. 2016 Nov 29;7(48):78499-78515. doi: 10.18632/oncotarget.12100.
4
[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].[PAX8、PAX2、p53和RAS在卵巢及输卵管中的表达及其对卵巢高级别浆液性癌起源的意义]
Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008.
5
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.卵巢浆液性交界性肿瘤中 KRAS(而非 BRAF)突变与复发性低级别浆液性癌相关。
J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.
6
CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.CD133、CD47 和 PD-L1 在卵巢高级别浆液性癌中的表达及其与转移疾病的关系:一项横断面研究。
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):249-255. doi: 10.31557/APJCP.2024.25.1.249.
7
Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.乳腺丝氨酸蛋白酶抑制剂和CD138在卵巢浆液性癌和透明细胞癌中的免疫组化表达
Tumour Biol. 2016 Apr;37(4):4889-900. doi: 10.1007/s13277-015-4333-y. Epub 2015 Nov 3.
8
Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.联合检测 TP53 和 AGR3 有助于鉴别卵巢高级别浆液性癌与低级别浆液性癌。
Int J Oncol. 2018 Jun;52(6):2041-2050. doi: 10.3892/ijo.2018.4360. Epub 2018 Apr 4.
9
Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.同期发生的卵巢浆液性交界性肿瘤和随后发生的浆液性癌的临床病理和分子特征。
Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325.
10
Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.浆液性交界性卵巢肿瘤的分子亚型表现出良性肿瘤和恶性肿瘤相关特征的明显表达模式。
Mod Pathol. 2014 Mar;27(3):433-42. doi: 10.1038/modpathol.2013.130. Epub 2013 Aug 16.

引用本文的文献

1
Diagnostic Potential of CD44, CD133, and VDR in Epithelial Ovarian Tumors: Association with Histopathology Parameters.CD44、CD133和维生素D受体在上皮性卵巢肿瘤中的诊断潜力:与组织病理学参数的关联
Int J Mol Sci. 2025 Apr 15;26(8):3729. doi: 10.3390/ijms26083729.
2
CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma.CD133 通过上调 Amphiregulin 促进黑色素瘤细胞增殖。
Cells. 2024 May 2;13(9):777. doi: 10.3390/cells13090777.
3
CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.

本文引用的文献

1
Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence.卵巢癌干细胞、上皮间质转化与肿瘤复发之间的关系。
Cancer Drug Resist. 2019 Dec 19;2(4):1127-1135. doi: 10.20517/cdr.2019.76. eCollection 2019.
2
Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.CD133 持续表达的耐化疗癌症干细胞样细胞在人卵巢癌中的特征。
Int J Mol Sci. 2020 Sep 4;21(18):6467. doi: 10.3390/ijms21186467.
3
Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas.
CD133、CD47 和 PD-L1 在卵巢高级别浆液性癌中的表达及其与转移疾病的关系:一项横断面研究。
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):249-255. doi: 10.31557/APJCP.2024.25.1.249.
4
A novel approach for transforming breast cancer stem cells into endothelial cells.一种将乳腺癌干细胞转化为内皮细胞的新方法。
Exp Ther Med. 2023 Dec 21;27(2):74. doi: 10.3892/etm.2023.12362. eCollection 2024 Feb.
5
Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets.揭开癌症干细胞的欺骗性本质:CD133 在揭示其秘密中的作用。
Int J Mol Sci. 2023 Jun 30;24(13):10910. doi: 10.3390/ijms241310910.
6
Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics.剖析并靶向癌症干细胞信号通路用于癌症治疗
Front Cell Dev Biol. 2023 May 25;11:1125174. doi: 10.3389/fcell.2023.1125174. eCollection 2023.
7
Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma.CD133 肿瘤干细胞标志物在 IDH 突变型和 IDH 野生型(异柠檬酸脱氢酶)星形细胞瘤中的表达。
Asian Pac J Cancer Prev. 2022 Sep 1;23(9):3051-3059. doi: 10.31557/APJCP.2022.23.9.3051.
癌症干细胞标志物CD133和CXCR4在骨肉瘤中的临床意义
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):67-73. doi: 10.31557/APJCP.2020.21.1.67.
4
Presence and role of stem cells in ovarian cancer.干细胞在卵巢癌中的存在及作用。
World J Stem Cells. 2019 Jul 26;11(7):383-397. doi: 10.4252/wjsc.v11.i7.383.
5
A Comprehensive Review of Ovarian Serous Carcinoma.卵巢浆液性癌的全面综述。
Adv Anat Pathol. 2019 Sep;26(5):329-339. doi: 10.1097/PAP.0000000000000243.
6
Ovarian cancer in the world: epidemiology and risk factors.全球卵巢癌:流行病学与风险因素
Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.
7
Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.加拿大不列颠哥伦比亚省上皮性卵巢癌女性的长期死亡率:一项基于人群的研究。
BMC Cancer. 2018 Oct 25;18(1):1039. doi: 10.1186/s12885-018-4970-9.
8
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
9
CD133: beyond a cancer stem cell biomarker.CD133:超越癌症干细胞标志物。
J Drug Target. 2019 Mar;27(3):257-269. doi: 10.1080/1061186X.2018.1479756. Epub 2018 Jul 17.
10
Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.癌症干细胞标志物在卵巢癌患者中的临床病理及预后意义:来自52项研究的证据
Cell Physiol Biochem. 2018;46(4):1716-1726. doi: 10.1159/000489586. Epub 2018 Apr 28.